Roy Cohen received his Ph.D. Summa Cum Laude in biochemistry from the Hebrew University in Jerusalem (Israel), where he applied cutting-edge biophysical methods to study how ion channels regulate neurotransmitter release, a process that allows neurons in the brain to communicate with each other.

Following the completion of his Ph.D., Dr. Cohen joined Cornell’s Chemistry and Chemical Biology Department for post-doctoral training, where he developed innovative techniques to study immune cell function, while gaining experience in translational research and nanotechnology.

Dr. Cohen has been leading the conception, invention and proliferation of TET into a platform technology that now enables rapid detection of multiple different classes of target analytes including enzymes, proteins, metabolites, and small molecules. Dr. Cohen also lead the invention and development of TETmedical’s innovative nucleic acid biosensors, creating a pioneering technology for rapid molecular detection of targets such as RNA and DNA signatures of pathogens and infectious disease, and micro-RNA biomarkers for various diseases.

With close to 30 years of biochemistry and biophysics experience, Dr. Cohen is now leading the R&D and clinical studies of multiple TET technologies with both human and veterinarian applications.

Dr. Cohen is an Assistant Research Professor at the Baker Institute (Baker Institute, Cornell), and in the Public and Environmental Health Department in Cornell university.